Zobrazeno 1 - 10
of 43
pro vyhledávání: '"Peter A. Forsberg"'
Publikováno v:
Clinical Case Reports, Vol 10, Iss 9, Pp n/a-n/a (2022)
Abstract Lenalidomide is an IMiD drug which has been associated with a variety of potential immune related complications. We describe the case of a patient with newly diagnosed multiple myeloma along with a history of systemic mastocytosis who develo
Externí odkaz:
https://doaj.org/article/c7e8a5dfa49440f1a7019de69e1a5b48
Publikováno v:
eJHaem, Vol 2, Iss 3, Pp 565-568 (2021)
Externí odkaz:
https://doaj.org/article/3da62ce45f864c279906bf1b84f18a6f
Autor:
Lauren T. Reiman, Zachary J. Walker, Lyndsey R. Babcock, Peter A. Forsberg, Tomer M. Mark, Daniel W. Sherbenou
Publikováno v:
Aging and Cancer, Vol 2, Iss 1-2, Pp 6-12 (2021)
Abstract The treatment of older persons with cancer is fraught by a delicate balance of targeting the disease while avoiding treatment‐related complications. “Personalized,” or “precision” medicine approaches can ease this problem through m
Externí odkaz:
https://doaj.org/article/925f760277ae49f193a8dcd6e13f00fa
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Multiple myeloma is an incurable hematologic malignancy. The typical disease course for myeloma patients is characterized by initial response to treatment followed by eventual development of resistance. Subsequent cycles of remission and relapse proc
Externí odkaz:
https://doaj.org/article/a54435f821694234aec5b41fc8cdeb26
Autor:
Lorraine Davis, Zachary J. Walker, Denis Ohlstrom, Brett M. Stevens, Peter A. Forsberg, Tomer M. Mark, Craig T. Jordan, Daniel W. Sherbenou
Publikováno v:
Journal of Clinical and Translational Science, Vol 6, Pp 54-54 (2022)
OBJECTIVES/GOALS: Immunomodulatory drugs (IMiDs) are critical to multiple myeloma (MM) disease control. IMiDs act by inducing Cereblon-dependent degradation of IKZF1 and IKZF3, which leads to IRF4 and MYC downregulation (collectively termed the “Ik
Externí odkaz:
https://doaj.org/article/f01e541e82b44b5ca415e89a489d9f7f
Autor:
Daniel W. Sherbenou, Peter A. Forsberg, Tomer M. Mark, Craig T. Jordan, Clayton A. Smith, Andrew Hammes, Shelby C. Bearrows, Denis Ohlstrom, Michael J. VanWyngarden, Brett M. Stevens, Lorraine N. Davis, Beau M. Idler, Zachary J. Walker
Supplemental Data
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba6c769e8b62a13e06d72a3f568be99b
https://doi.org/10.1158/1078-0432.22479033.v1
https://doi.org/10.1158/1078-0432.22479033.v1
Autor:
Daniel W. Sherbenou, Peter A. Forsberg, Tomer M. Mark, Craig T. Jordan, Clayton A. Smith, Andrew Hammes, Shelby C. Bearrows, Denis Ohlstrom, Michael J. VanWyngarden, Brett M. Stevens, Lorraine N. Davis, Beau M. Idler, Zachary J. Walker
Purpose:The prognosis of patients with multiple myeloma who are resistant to proteasome inhibitors, immunomodulatory drugs (IMiD), and daratumumab is extremely poor. Even B-cell maturation antigen–specific chimeric antigen receptor T-cell therapies
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c59e97f02f97100eb593367a65da4fed
https://doi.org/10.1158/1078-0432.c.6530112
https://doi.org/10.1158/1078-0432.c.6530112
Autor:
Alana Keller, Olivia Perez De Acha, Lauren T Reiman, Zachary J Walker, David S Jayabalan, Ruben Niesvizky, Peter A Forsberg, Peter Kim, Kamlesh Bisht, Hongfang Wang, Helgi van de Velde, Daniel W. Sherbenou
Publikováno v:
Blood. 140:7097-7099
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4f401a52853f42433bde263aab89c4bd
https://doi.org/10.1182/blood-2022-169072
https://doi.org/10.1182/blood-2022-169072
Autor:
Alexander M Lesokhin, Joshua Richter, Suzanne Trudel, Adam D Cohen, Andrew Spencer, Peter A Forsberg, Jacob P Laubach, Sheeba K Thomas, Nizar J. Bahlis, Luciano J. Costa, Paula Rodriguez Otero, Maria-Victoria Mateos, Jesus G Berdeja, Rayan Kaedbey, Amrita Y. Krishnan, Rafael Fonseca, Voleak Choeurng, James Cooper, Teiko Sumiyoshi, Chihunt Wong, Simon J Harrison
Publikováno v:
Blood. 140:4415-4417
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0ee46f74375fbb1d7a20b4434584089a
https://doi.org/10.1182/blood-2022-157547
https://doi.org/10.1182/blood-2022-157547
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:e630-e634
Clinical Practice Points • Selinexor may be active even in the dire situation of early relapse after allogeneic stem cell transplantation. • Selinexor retains activity in patients who are proteasome, immunomodulatory drug, and daratumumab refract
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::39d5d5f7e068e53b953e14eca2bd9ab5
https://doi.org/10.1016/j.clml.2021.03.001
https://doi.org/10.1016/j.clml.2021.03.001